Investment Rating - The report maintains a "Recommended" rating for the company Fuhong Hanlin (stock code: 2696.HK) [1] Core Insights - Fuhong Hanlin reported a revenue of 6.667 billion yuan for 2025, representing a year-on-year growth of 16.5%, and a net profit of 827 million yuan, with a slight increase of 0.8% [4] - The company has achieved continuous revenue and profit growth for three consecutive years since it first became profitable in 2023 [4] - The global product revenue reached 5.775 billion yuan, with a year-on-year increase of 17.0%, driven by significant sales of core products [4] - The company’s R&D investment for the year was 2.492 billion yuan, reflecting a 35.4% increase year-on-year [4] - The report highlights the successful internationalization of core products, particularly HLX43 and trastuzumab, which have seen substantial overseas sales growth [4] Financial Performance Summary - The company’s projected financial performance for 2026-2028 includes: - Revenue: 8.059 billion yuan in 2026, 7.786 billion yuan in 2027, and 9.486 billion yuan in 2028 - Net profit: 1.018 billion yuan in 2026, 982 million yuan in 2027, and 1.255 billion yuan in 2028 - The projected PE ratios are 34, 36, and 28 for the years 2026, 2027, and 2028 respectively [5] - The gross margin is expected to remain strong, with estimates of 76.43% in 2026 and 74.98% in 2027 and 2028 [5] Product and Market Development - The report emphasizes the global sales performance of key products: - Sales of HLX43 reached 1.493 billion yuan, with a year-on-year growth of 13.7% - Trastuzumab sales amounted to 2.9645 billion yuan, showing a 5.5% increase, and it is now included in multiple national insurance systems [4] - The sales of neratinib surged by 564.2% to 301.2 million yuan, solidifying its position in the HER2-positive early breast cancer treatment market [4] - The company is actively exploring the potential of its innovative pipeline, including ADC and monoclonal antibodies, with promising data presented at international academic conferences [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 自願公告 帕妥珠單抗生物類似藥HLX11 （重組抗HER2結構域II人源化單克隆抗體注射液） 獲歐洲藥品管理局(EMA)人用醫藥產品 委員會(CHMP)積極審評意見 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 茲提述本公司於2025年3月28日刊發的公告，內容有關本公司自主研發的 Perjeta® （帕妥珠單抗）生物類似藥候選藥HLX11（重組抗HER2結構域II人源 化單克隆抗體注射液）（「HLX11」）適用於：(1)與曲妥珠單抗和化療聯合(i)用 於HER2陽性、局部晚期、炎性或早期乳腺癌且具有高復發風險成人患者的 新輔助治療；以及(ii)用於具有高復發風險 ...

Core Viewpoint - Gan Li Pharmaceutical and its European subsidiary have received a positive opinion from the CHMP for the marketing authorization applications of their rapid-acting insulin products, marking a significant advancement in their entry into the European diabetes treatment market [1][2]. Group 1: Product Development and Approval - The CHMP's positive opinion is a crucial step towards obtaining EU marketing authorization for the rapid-acting insulin products, Bysumlog® and Dazparda®, which are intended for diabetes treatment in adults and children [1]. - The CHMP recommends the approval of Bysumlog® as a biosimilar to Humalog® and Dazparda® as a biosimilar to NovoRapid®, indicating their potential to meet the needs of diabetes patients in Europe [1][2]. Group 2: Market Potential - The European diabetes treatment market presents significant clinical demand and market potential, with an estimated 65.6 million diabetes patients in Europe by 2024, representing 11.1% of the global total [2]. - The total medical expenditure related to diabetes in Europe is projected to reach $193 billion, with an average annual expenditure of $2,951 per patient, highlighting the lucrative market opportunity for the new insulin products [2]. Group 3: Competitive Landscape - The insulin market in Europe is characterized by an oligopolistic structure, with Eli Lilly dominating the market for rapid-acting insulin (Bysumlog®) and Novo Nordisk leading in the supply of Dazparda® [2]. - Eli Lilly's global sales for rapid-acting insulin are expected to reach approximately $2.325 billion in 2024, while Novo Nordisk's sales for Dazparda® are projected to be around $2.524 billion in 2025 [2]. Group 4: Investment and R&D - Gan Li Pharmaceutical has invested approximately 410 million RMB in the R&D of Bysumlog® and 212 million RMB in Dazparda® as of September 30, 2025, indicating a strong commitment to product development [3]. - Despite the positive opinion from CHMP, the company acknowledges uncertainties regarding the final approval from the EC and the commercial viability of the products in the competitive European market [3].

Core Viewpoint - Hualan Biological (002007.SZ) announced that its subsidiary Hualan Ankang received the Clinical Trial Approval Notice from the National Medical Products Administration, allowing the clinical trial of the biosimilar drug Pembrolizumab injection to proceed [1] Group 1: Clinical Trial Approval - The approval signifies that the drug can officially commence corresponding clinical research to further validate its safety and efficacy, laying the groundwork for subsequent registration and market launch [1] - Pembrolizumab injection is a biosimilar developed by Merck and is one of the first PD-1 inhibitors approved globally [1] - Currently, there are no similar drugs approved for market in China, aside from the original product [1] Group 2: Product Pipeline and Structure - The approval enriches the company's product pipeline and optimizes its product structure [1] - The drug development process is characterized by long cycles, multiple stages, and high risks, necessitating the completion of all clinical trials, production applications, and approvals from the National Medical Products Administration [1] Group 3: Risks and Challenges - There are uncertainties associated with the outcomes of each stage, including clinical data and progress not meeting expectations, intense market competition, and changes in industry policies and technology [1]

Group 1 - The core announcement is that Baiotai Biopharmaceutical Co., Ltd. has received marketing approval from the European Medicines Agency (EMA) for GotenfiaR (BAT2506, Golimumab injection) [1][2] - GotenfiaR is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis [2] - BAT2506 is a biosimilar developed according to guidelines from the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and EMA, targeting TNF-α to inhibit its activity [2] Group 2 - The marketing authorization application for BAT2506 has been accepted by NMPA, FDA, and Brazil's National Health Surveillance Agency, with commercialization partnerships covering 115 countries and regions [2] - The approval of GotenfiaR is expected to enhance the company's international market presence and positively impact long-term operational performance [2] - The company acknowledges potential competition from already marketed and other potential competing products, which may have first-mover advantages [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for its self-developed HLX15-SC, a subcutaneous injection of a recombinant anti-CD38 fully human monoclonal antibody, for the treatment of multiple myeloma [1] Group 1: Product Development - HLX15 is a biosimilar to daratumumab, designed for the treatment of multiple myeloma (MM) [1] - The mechanism of action for daratumumab includes binding to CD38 on tumor cells, inducing apoptosis through various immune-related mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) [1] - The company successfully completed a Phase I clinical study of HLX15-IV (intravenous formulation) in healthy male subjects in China in June 2024 [1] Group 2: Market Potential - According to IQVIA MIDAS, the global sales of daratumumab are projected to be approximately $12.88 billion in 2024 [1]

Group 1 - The core point of the article is that Baiotai (688177.SH) has signed a licensing and commercialization agreement with Avalon Pharma for its BAT3306 (pembrolizumab) injection in the Saudi and MENA markets, with potential total payments up to $7 million [1][2] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a percentage of net sales as revenue sharing [1] - BAT3306 is developed based on guidelines from NMPA, FDA, and EMA for biosimilars and is an immuno-oncology drug classified as a humanized monoclonal antibody [1] Group 2 - The purpose of the agreement is to quickly convert the company's R&D achievements into economic benefits through commercial cooperation and licensing [2] - The collaboration with Avalon is expected to integrate advantages in R&D, production quality control, technology enhancement, clinical application, and commercial promotion, creating favorable conditions for the company's future development [2] - The successful implementation of the agreement is anticipated to have a positive impact on the company's future operating performance [2]

Group 1 - The core point of the article is that Baiotai (688177.SH) has signed a licensing and commercialization agreement with Avalon Pharma for its BAT3306 (Pabrolizumab) injection in the Saudi and Middle East and North Africa markets, with potential total payments up to $7 million [1][2] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a two-digit percentage of net sales as revenue sharing [1] - BAT3306 (Pabrolizumab) is developed based on guidelines for biosimilars from the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) [1] Group 2 - The purpose of the agreement is to quickly transform the company's research and development achievements into economic benefits through commercial cooperation and licensing [2] - The collaboration with Avalon is expected to integrate advantages in research, production quality control, technology enhancement, clinical application, and commercial promotion, creating favorable conditions for the company's future development [2] - The successful implementation of the agreement is anticipated to have a positive impact on the company's future operating performance [2]

Group 1 - The core point of the article is that Baiotai has signed a licensing and commercialization agreement with Avalon for its BAT3306 (Pabrolizumab) injection, granting Avalon exclusive commercialization rights in Saudi Arabia and the MENA region, with potential total payments up to $7 million [1] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a percentage of net sales as revenue sharing [1] Group 2 - BAT3306 (Pabrolizumab) is a humanized monoclonal antibody drug developed according to guidelines from NMPA, FDA, and EMA for biosimilars, functioning as an immune checkpoint inhibitor [2] - The drug specifically binds to the PD-1 receptor on lymphocytes, blocking its interaction with PD-L1 and PD-L2, thereby reactivating T cells against tumor cells for cancer treatment [2] - The company is conducting a multicenter, randomized, double-blind, parallel-controlled clinical study to evaluate the pharmacokinetics, immunogenicity, safety, and efficacy of BAT3306 compared to US-Ketruda® in patients with stage IB-IIIA non-small cell lung cancer [2]

Core Viewpoint - The company focuses on innovative treatments for mature targets, aiming to differentiate itself in the competitive PD-(L)1 market, particularly with its PD-1 monoclonal antibody, which is set to be the first and only approved treatment for ES-SCLC in the EU by February 2025 [1] Group 1: Innovative Drug Pipeline - The PD-1 monoclonal antibody is targeting small cell lung cancer as a core differentiation track while also expanding into new indications, potentially becoming the first immunotherapy approved for perioperative gastric cancer and first-line colorectal cancer [1] - HLX07, an engineered EGFR monoclonal antibody, has an extended half-life allowing for a three-week dosing schedule alongside H drug, showing excellent efficacy and safety in treating refractory squamous non-small cell lung cancer [1] - HLX43, a PD-L1 ADC with a dual toxin release mechanism, has shown superior anti-tumor efficacy and manageable safety in Phase I trials, with multiple Phase II trials for mainstream cancers like non-small cell lung cancer and liver cancer poised to start [1] Group 2: Biosimilar Drug Pipeline - The company has a long-standing commitment to the biosimilar drug sector and is advancing its global strategy, with HLX14 (dexamethasone) already approved in Europe and the US, and HLX11 (pertuzumab) approved in the US with applications pending in China and Europe [2] - The pipeline also includes targets like CTLA-4 and CD38, with ongoing overseas clinical studies to support global market expansion [2] Group 3: Financial Forecast - The company anticipates continued revenue contributions from its biosimilar drugs and accelerated innovation drug development, projecting revenues of 6.009 billion, 5.999 billion, and 6.438 billion yuan for 2025-2027, with net profits of 798 million, 804 million, and 839 million yuan respectively, corresponding to PE ratios of 47, 46, and 45 times [2]